Victory Oghenetega Samuel

Ms. Victory Oghenetega Samuel

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
Tomi Lois AdetunjiTomi Lois Adetunji
Tomi Lois Adetunji
MAMarvellous Amarachi Acho
Marvellous Amarachi Acho
Victory Oghenetega SamuelVictory Oghenetega Samuel
Victory Oghenetega Samuel
Chinemerem Ruth OhoroChinemerem Ruth Ohoro
Chinemerem Ruth Ohoro
MRMmbulaheni Ramulondi
Mmbulaheni Ramulondi
Erythrina velutina Willd., commonly known as "mulungu" in Brazil, is a leguminous tree with various traditional medicinal uses. These uses include treating insomnia, central nervous system disorders, convulsions, nervous cough, and inflammation. This review aims to comprehensively summarize the ethnomedicinal uses, chemical constituents, pharmacology, and toxicology of E. velutina to explore its potential as a source for new therapeutic agents. Information was collected from scientific databases, dissertations, and books. Chemical structures were generated using ChemDraw. To ensure the accuracy of the plant names, "World Flora Online" (www.worldfloraonline.org) was consulted for the accepted names of plants. E. velutina is indigenous to Brazil, Peru, Ecuador, Colombia, Venezuela, and Hispaniola. Approximately 244 compounds, mainly alkaloids and flavonoids, have been isolated from it. The plant and its extracts have exhibited various bioactivities, such as anti-inflammatory, anxiolytic, anticonvulsant, neuroprotective, analgesic, antimicrobial, and antioxidant effects, validating some of its traditional medicinal uses. Erythrina velutina shows promising therapeutic potential for conditions like convulsion, central nervous disorders, anxiety, insomnia, and inflammation, primarily due to its alkaloid and flavonoid content. The traditional medicinal uses of the plant, combined with modern scientific research, underscore its pharmacological potential. This makes it a significant candidate for drug development. Further research should focus on conducting toxicological studies, clinical trials, and mechanistic investigations. These efforts will enable a comprehensive exploration of its pharmacological properties and potential applications in drug development.

17 December 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Victory Oghenetega SamuelVictory Oghenetega Samuel
Victory Oghenetega Samuel
RSRegan Hi Solomons
Regan Hi Solomons
SMShayne Mason
Shayne Mason
Objective: To investigate metabolic markers linked to Mycobacterium tuberculosis (M. tb) in the cerebrospinal fluid (CSF) of a South African cohort of paediatric tuberculous meningitis (TBM). Methods: Targeted proton magnetic resonance (1H-NMR) spectroscopy and two-dimensional gas chromatography coupled with time-of-flight mass spectrometry (GCxGC-TOFMS) metabolomics approaches were used to evaluate M. tb-linked metabolites in the CSF of 21 definite cases of TBM and 25 control cases. Uni- and multivariate statistical analyses were performed. Results: Four statistically significant metabolites were identified to discriminate TBM cases from controls. Mannose and arabinose were found at lower concentrations in the TBM group. Nonanoic acid and propanoic acid were found in higher concentrations in the definite TBM group. Conclusions: We identified the novel presence of nonanoic acid for the first time as a M. tb-linked marker in the CSF of cases of TBM, possibly as a degradation product of the M. tb cell wall. Propanoic acid can be related to perturbed brain neuro-energetics and neuro-inflammation in TBM cases and is likely a host-response metabolite. Mannose and arabinose–supposed surrogates for lipoarabinomannan, a component of the M. tb cell wall–were not reliable markers for M. tb. Further research should focus on the analysis of fatty acids in the CSF of patients with TBM.

Verified
Journal Article
Open access
PDF file
Victory Oghenetega SamuelVictory Oghenetega Samuel
Victory Oghenetega Samuel
Abdullahi Adeyinka AdejareAbdullahi Adeyinka Adejare
Abdullahi Adeyinka Adejare
UUUshotanefe Useh
Ushotanefe Useh
Newborn screening initiatives have the potential to mitigate childhood morbidity in Africa, but they also have special ethical, legal, and social implications (ELSI) that are influenced by issues with the health system, cultural diversity, and limited resources. This scoping review explores the ELSI of newborn screening across Africa to identify key challenges, gaps, and future research needs. A systematic search identified 27 peer-reviewed studies published between 2008 and 2025, covering 12 African countries. Data were extracted on study characteristics, disease types, and ELSI dimensions from African Journals Online (AJOL), Scopus, PubMed, Web of Science, and BMJ Journals. Thematic analysis mapped recurring ethical, legal, and social concerns. Most studies examined ethical and social dimensions, while legal frameworks were rarely addressed. South Africa, Tanzania, and Ghana contributed the largest number of publications. Sickle cell disease (52%) and hearing screening (30%) were the dominant foci. Common ethical issues included informed consent, privacy, and justice; legal gaps centered on the absence of data protection and frameworks; and social concerns involved stigma, awareness, and cultural perceptions of hereditary disease. Ethical and social issues dominate NBS discourse in Africa, whereas legal oversight remains limited. To guarantee fair, reliable, and long-lasting newborn screening programs, national policy guidelines, community involvement, and context-specific ethical frameworks must be strengthened.